The achievement of a pathological complete response (pCR) after NAC is associated with a better prognosis than is non-pCR in patients with HER-2-positive and triple-negative (TN) breast cancers, but not in those with the luminal subtype [13]. Here, ERBB2 is linked to breast cancer.